Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients age 18 to 80 years, inclusive. Patients, age 81 to 85 years, inclusive, may be included on a case-by-case basis if their health status is determined to be stable after consultation with the Medical Monitor.~* Patients with end-stage renal disease receiving hemodialysis via CVC.~* Patients must be expected to receive hemodialysis through a direct or cuffed, tunneled dual lumen catheter or 2 cuffed, tunneled single lumen catheters for a minimum of 45 catheter-days after Day 1.~* Patients must have been receiving dialysis for a minimum of 6 dialysis sessions at the study center dialysis clinic prior to the signing of the Informed Consent Form (ICF).~* Patients must have received dialysis at their prescribed blood flow rate (+/- 10%) for at least 2 consecutive dialysis sessions prior to signing the ICF.~* Patients must have 2 screening pre-pump arterial pressure measurements (collected during the first 20 minutes of dialysis) that differ by less than or equal to (≤) 20 mmHg at 2 consecutive dialysis sessions when receiving dialysis at their prescribed blood flow rate (+/- 10%) prior to randomization.~Exclusion Criteria:~* Clinical signs and/or symptoms of a local or systemic infection within 14 days prior to Day 1.~* Evidence of infection of the catheter exit site/tunnel within 14 days prior to Day 1.~* Patients who have received systemic antibiotics within 14 days prior to Day 1.~* History of fever (T \> 37.5°C) or chills within 14 days prior to Day 1.~* An occluded catheter (blood flow inadequate for dialysis) or a catheter that required thrombolytic treatment within 14 days prior to Day 1.~* A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic agent, including heparin.~* A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic agent, including heparin.~* Catheters that are deemed by their manufacturers to be incompatible with alcohol-containing solutions. These include, but are not limited to:~  1. Angiodynamics - LifeJet® VP VascPak Catheter.~ 2. Angiodynamics - Schon™ Chronic Hemodialysis Catheter.~ 3. Angiotech - Hemostream™ Chronic Dialysis Catheter.~ 4. Bard - all Bard Catheters.~* The use of TEGO® or TEGO-like catheter caps. Patients may be switched to standard catheter caps in order to participate in this study.~* Patients with a known or documented allergy to TMP or TMP-containing drugs, ethanol, ethylene diamine tetraacetic acid (EDTA), propylene glycol and/or glycerin.~* Patients with a history of heparin-induced thrombocytopenia or in whom the use of heparin is contraindicated. (Note: If the use of heparin is restricted for only a specified period of time, the patient may be enrolled at a later date when the use of heparin is no longer contraindicated.)~* Evidence of acute/ongoing hepatic injury (alanine aminotransferase \[ALT\] \> 300 IU/L) or chronic hepatic insufficiency (Total bilirubin \> 2.0 mg/dL and/or albumin \< 3.0 g/dL during Screening or within 30 days prior to Screening). Note: A patient whose albumin level is low solely due to nephrotic syndrome may be enrolled (with Medical Monitor approval) if the albumin level has been stable for at least 3 months prior to ICF signature.~* Patients who the Investigator believes have a prognosis for survival of less than 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- B-Lock (IMD) (Type: EXPERIMENTAL): Investigational Medical Device (IMD)
- Heparin 5,000 U/mL (ACH) (Type: ACTIVE_COMPARATOR): Active Comparator Heparin (ACH)

Based on this trial design, predict the completion outcome and termination type (if applicable).